We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$296M
Cap. Flow %
-12.4%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 90.67%
2 Consumer Discretionary 6.64%
3 Financials 0.85%
4 Consumer Staples 0.31%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
26
Gossamer Bio
GOSS
$96.5M
$20.5M 0.86%
2,358,968
– –
RUBY
27
DELISTED
Rubius Therapeutics, Inc
RUBY
$20.4M 0.85%
3,701,580
– –
TRML
28
DELISTED
Tourmaline Bio
TRML
$20.3M 0.85%
206,426
– –
NTLA icon
29
Intellia Therapeutics
NTLA
$1.49B
$20M 0.84%
275,000
– –
DNLI icon
30
Denali Therapeutics
DNLI
$3.8B
$19.3M 0.81%
600,000
– –
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.84B
$18.9M 0.79%
800,100
-449,900
-36% -$12.7M
EVO icon
32
Evotec
EVO
$686M
$17.4M 0.73%
1,149,425
– –
KURA icon
33
Kura Oncology
KURA
$794M
$16.9M 0.71%
1,050,000
– –
EQRX
34
DELISTED
EQRx, Inc. Common Stock
EQRX
$16.5M 0.69%
4,000,000
– –
KLRS
35
Kalaris Therapeutics
KLRS
$79.7M
$15.7M 0.66%
101,016
– –
REPL icon
36
Replimune Group
REPL
$440M
$15.3M 0.64%
900,000
– –
INTC icon
37
CALL
Intel
INTC
$421B
$14.9M 0.62%
300,000
– –
OMGA
38
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$14.2M 0.59%
2,273,530
– –
APTX
39
DELISTED
Aptinyx Inc. Common Stock
APTX
$13.9M 0.58%
6,116,493
– –
NBP
40
NovaBridge Biosciences American Depositary Shares
NBP
$192M
$13.8M 0.58%
850,000
– –
AGEN
41
Agenus
AGEN
$274M
$13.5M 0.57%
280,225
-50,950
-15% -$2.75M
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
$12.9M 0.54%
400,000
-144,047
-26% -$5.23M
AUPH icon
43
Aurinia Pharmaceuticals
AUPH
$1.93B
$12.4M 0.52%
1,000,000
– –
PRAX icon
44
Praxis Precision Medicines
PRAX
$8.2B
$12.3M 0.51%
80,000
– –
KRON
45
DELISTED
Kronos Bio
KRON
$11.2M 0.47%
1,542,954
– –
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
$10.2M 0.43%
+200,000
New +$8.83M
RPTX
47
DELISTED
Repare Therapeutics
RPTX
$9.97M 0.42%
700,000
– –
IMA
48
ImageneBio Inc
IMA
$64M
$9.45M 0.4%
129,126
– –
MRNS
49
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$9.35M 0.39%
1,000,000
– –
FMTX
50
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$9.3M 0.39%
1,000,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $296M in Q1 2022, closing 20 positions and reducing 11 holdings. Its most notable exit was NovaGold Resources, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Vigil Neuroscience worth $7.88M.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.